Cite
Immunological response to covid‐19 vaccination in ovarian cancer patients receiving parp inhibitors
MLA
Liontos, M.Terpos, E.Markellos, C.Zagouri, F.Briasoulis, A.Katsiana, I.Skafida, E.Fiste, O.Kunadis, E.Andrikopoulou, A.Kaparelou, M.Koutsoukos, K.Gavriatopoulou, M.Kastritis, E.Trougakos, I. P.Dimopoulos, M. A. Immunological Response to Covid‐19 Vaccination in Ovarian Cancer Patients Receiving Parp Inhibitors. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..f9ec6d0245160383deae33927d93380a&authtype=sso&custid=ns315887.
APA
Liontos, M. T. E. M. C. Z. F. B. A. K. I. S. E. F. O. K. E. A. A. K. M. K. K. G. M. K. E. T. I. P. D. M.-A. (2021). Immunological response to covid‐19 vaccination in ovarian cancer patients receiving parp inhibitors.
Chicago
Liontos, M. Terpos, E. Markellos, C. Zagouri, F. Briasoulis, A. Katsiana, I. Skafida, E. Fiste, O. Kunadis, E. Andrikopoulou, A. Kaparelou, M. Koutsoukos, K. Gavriatopoulou, M. Kastritis, E. Trougakos, I.P. Dimopoulos, M.-A. 2021. “Immunological Response to Covid‐19 Vaccination in Ovarian Cancer Patients Receiving Parp Inhibitors,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..f9ec6d0245160383deae33927d93380a&authtype=sso&custid=ns315887.